HALO · Investment summary · as of 5 August 2026
Priced below what the business already delivers
Business type: Compounder · mature and structurally stable
Size is the strategy's, set against its own position and exposure limits.
At $83.23, HALO requires a -3% five-year revenue growth rate to justify its enterprise value — less than the business already delivers, at 39%.
The disagreement with the market is entirely about revenue DURABILITY past the 2027 rHuPH20 patent expiry, not about margins — the margin axis passes with 52.06pp of slack and nobody disputes HALO's margins.
The value rests on an exit multiple of 19.7x, a terminal operating margin of 50% and a 5.9% cost of capital. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.
The strongest argument against this view: The royalty stream stops compounding and becomes a run-off annuity because the CONTRACTUAL rate steps down and is not replaced.
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | The disagreement with the market is entirely about revenue DURABILITY past the 2027 rHuPH20 patent expiry, not about margins — the margin axis passes with 52.06pp of slack and nobody disputes HALO's margins. |
| What do we forecast? | Revenue growth of 39% demonstrated; a terminal operating margin of 50%; an exit multiple of 19.7x. |
| What does Street forecast? | Not determined — no consensus estimates are joined to this record |
| Where do we differ? | On revenue growth, the difference between what the price requires and what the business has demonstrated is +41.9 percentage points. |
| What is it worth? | Twelve-month target $106.50, +28% from the struck price. Scenario-weighted expected return net of costs +28.0%. |
| Why now? | Date not announced — no dated event that would resolve the disagreement is on file |
| Date or window | Event | Thesis confirmed if | Thesis weakened or refuted if |
|---|---|---|---|
| Q4-2026 results / FY2027 guidance, Jan-Feb 2027 | FY2027 guided total revenue | FY2027 guidance, when issued in Jan-Feb 2027, implies total revenue at or above $1.95bn | FY2027 guidance, when issued in Jan-Feb 2027, implies total revenue below $1.95bn |
| any quarter of FY2027 | Royalty revenue YoY | Neither leg of the condition opposite is met at this date | Quarterly royalty revenue declines year-over-year in any quarter of 2027 |
| any quarter from Q1-2027 | DARZALEX royalty, disclosed quarterly | DARZALEX royalty revenue declines no more than 15% YoY in any quarter after the US patent expiry | DARZALEX royalty revenue declines more than 15% YoY in any quarter after the US patent expiry |
| any period | Collaboration terminations disclosed in 8-K or 10-Q | Neither leg of the condition opposite is met at this date | A partner terminates an ENHANZE collaboration covering a marketed product |
The royalty stream stops compounding and becomes a run-off annuity because the CONTRACTUAL rate steps down and is not replaced.
Estimated probability 20%, against the 25% level at which the position would be resized. It sits within that level.
Falsifiable and fundamental — not one of them is a price condition.
On approach to the $106.50 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default. The position is trimmed once forward expected return falls below 0% net of costs, because the capital has a better use elsewhere in the book.
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Met | Is the business worth owning under its declared economic type? |
| Valuation | Met | Is the operating path required by today's price achievable? |
| Liquidity | Met | Can the intended position be built and exited in the right vehicle? |
| Downside | Met | The royalty stream stops compounding and becomes a run-off annuity because the CONTRACTUAL rate steps down and is not replaced. |
| Momentum | Not determined | Does price action support or complicate entry timing? Not established on the evidence on file. |
| Catalyst | Not determined | Is there a dated event that resolves the disagreement? Not established on the evidence on file. |
| Consensus | Not determined | Is the house-versus-Street disagreement identified and quantified? Not established on the evidence on file. |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The strongest case for mispricing is that the business already delivers +41.9 percentage points more growth than the price requires. The most important unresolved uncertainty is the permanent-loss mechanism: the royalty stream stops compounding and becomes a run-off annuity because the CONTRACTUAL rate steps down and is not replaced. The next evidence that should change the portfolio decision is the next scheduled results, or a daily close below $73.24, which forces an immediate review.